A Harvard Stem Cell Institute study comparing how blood stem cells and leukemia cells consume nutrients found that cancer cells are far less tolerant of shifts in their energy supply than their normal counterparts. The results suggest there could be ways to target and kill cancer cells without affecting healthy cells.
Studies begun by Harvard Stem Cell Institute scientists eight years ago have led to a report that may be a major step in developing treatments for amyotrophic lateral sclerosis, or Lou Gehrig’s disease.
Harvard-affiliated researchers have identified a way to enhance regrowth of human corneal tissue to restore vision, using a molecule that acts as a marker for hard-to-find limbal stem cells.
A team at Harvard Stem Cell Institute recently found that transplanting mesenchymal stem cells along with blood-vessel-forming cells naturally found in circulation improves results. This co-transplantation keeps the mesenchymal stem cells alive longer in mice after engraftment, up to a few weeks compared with hours without co-transplantation.
Harvard Stem Cell Institute scientists collaborating with researchers at the University of Pennsylvania have developed a “genome-editing” approach for permanently reducing cholesterol levels in mice through a single injection, a development with the potential to reduce the risk of heart attacks in humans by 40 to 90 percent.
Divinity School graduate Shelley Brown is combining her love for science and religion to help stitch together two fields that rarely seem to meet.
The Harvard Stem Cell Institute is now 10 years old. What began as an idea embracing cross-disciplinary research quickly became a generator of scientific discoveries.
Harvard scientists have merged stem cell and “organ-on-a-chip” technologies to grow, for the first time, functioning human heart tissue carrying an inherited cardiovascular disease. The research appears to be a big step forward for personalized medicine, because it is working proof that a chunk of tissue containing a patient’s specific genetic disorder can be replicated in the laboratory.
Researchers at the Harvard Stem Cell Institute have shown that a protein, one they previously demonstrated can make failing hearts in aging mice appear more like those of young and healthy mice, similarly improves brain and skeletal muscle function in aging mice.
Harvard Stem Cell Institute researchers at Boston Children’s Hospital have reprogrammed mature blood cells from mice into blood-forming hematopoietic stem cells (HSCs), using a cocktail of eight genetic switches called transcription factors. The reprogrammed cells have the functional hallmarks of HSCs and are able to self-renew like those cells.
Myelin, the electrical insulating material in the body long known to be essential for the fast transmission of impulses along the axons of nerve cells, is not as ubiquitous as thought, according to new work led by Professor Paola Arlotta.
Harvard stem cell scientists have discovered that a recently approved medication for epilepsy might be a meaningful treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, a uniformly fatal neurodegenerative disorder.
A Harvard research team led by Kevin Kit Parker, a Harvard Stem Cell Institute principal faculty member, has identified a set of 64 crucial parameters by which to judge stem cell-derived cardiac myocytes, making it possible for scientists and pharmaceutical companies to quantitatively judge and compare the value of stem cells.
Harvard stem cell scientists have successfully converted skins cells from patients with early onset Alzheimer’s into the types of neurons affected by the disease, making it possible for the first time to study this leading form of dementia in living human cells.
Harvard stem cell scientists studying the effect of nitric oxide on liver growth and regeneration appear to have serendipitously discovered a markedly improved treatment for liver damage caused by acetaminophen toxicity.
Research by Harvard Stem Cell Institute scientists shows that much lincRNA, which had been generally believed useless, plays an important role in the genome.
Harvard stem cell scientists have discovered that the same chemicals that stimulate muscle development in zebrafish can be used to differentiate human stem cells into muscle cells in the laboratory, which makes muscle cell therapy a more realistic clinical possibility.
They began with a discovery in zebrafish in 2007, and now researchers at the Harvard Stem Cell Institute (HSCI) have published initial results of a Phase Ib human clinical trial of a therapeutic that could improve the success of blood stem cell transplantation. This marks the first time that HSCI has carried a discovery from the lab bench to the clinic.
An international scientific collaborative led by the Harvard Stem Cell Institute’s Kornelia Polyak has discovered why women who give birth in their early 20s are less likely to develop breast cancer than women who don’t, triggering a search for a way to confer this protective state on all women.
Amy Wagers and Emmanuelle Passegué have found that cancer stem cells actively remodel the environment of bone marrow, where blood cells are formed, so that it is hospitable only to diseased cells. This finding could influence the effectiveness of bone marrow transplants.
Harvard Stem Cell Institute researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity.
With plans to develop a career in medical research, Jennifer Cloutier is graduating from Harvard with her interest reinforced on research and medicine.
After college, Joshua Wortzel plans to build upon his Harvard research that focused on tissue regeneration. He hopes to work in translational medicine, helping to create drugs that might augment patients’ lives.
In the nine years since its founding, The Harvard Stem Cell Institute has become the world leader in stem cell biology.
Two Harvard Stem Cell Institute researchers have identified a protein in the blood of mice and humans that may prove to be the first effective treatment for the form of age-related heart failure that affects millions of Americans, a study says.
Researchers at the Harvard Stem Cell Institute have discovered a hormone that holds promise for a dramatically more effective treatment of type 2 diabetes, a metabolic illness afflicting an estimated 26 million Americans.
Using a new, stem cell-based, drug-screening technology that could reinvent and greatly reduce the cost of developing pharmaceuticals, researchers at the Harvard Stem Cell Institute have found a compound that is more effective in protecting the neurons killed in amyotrophic lateral sclerosis than are two drugs that failed in human clinical trials.
Harvard stem cell biologists have proven that it is possible to turn one type of already differentiated neuron into another inside the brain, and their findings may have enormous implications for the treatment of neurodegenerative diseases.
A Harvard panel examined the problem of clinics around the world that provide stem cell treatments for intractable conditions. Although there is no medical evidence of the treatments’ effectiveness, such clinics have drawn thousands of patients from many countries.
A new study describes the mechanism behind impaired muscle repair during aging and a strategy that may help rejuvenate aging tissue by manipulating the environment in which muscle stem cells reside.
A consortium of scientists at 20 institutions, led by a principal faculty member at the Harvard Stem Cell Institute, has used stem cells to take a major step toward developing personalized medicine to treat Parkinson’s disease.
Harvard stem cell researchers at Massachusetts General Hospital have taken a critical step toward discovering in the relatively near future a drug to control cystic fibrosis, a fatal lung disease that claims about 500 lives each year, with 1,000 new cases diagnosed annually.
The twin epidemics of obesity and its cousin, diabetes, have been the target of numerous studies at Harvard and its affiliated hospitals and institutions. Harvard researchers have produced a dizzying array of findings on the often related problems.
Four years ago, Harvard’s Office of Technology Development launched its Accelerator Fund, a $10 million revolving account to be used as a bridge across the “valley” between creation and development. The fund is proving to be just such a bridge.
Doug Melton Thomas Dudley Cabot Professor of the Natural Sciences at Harvard University and co-Director of the Harvard Stem Cell Institute
In a new study, Harvard stem cell researchers and scientists at the University of Cambridge have found that the age-related degeneration in conditions such as multiple sclerosis (MS) may be reversible.
Gordon Jones, director of the new Harvard Innovation Lab, has ideas on how to foster an entrepreneurial mentality at the country’s oldest university.
Five years after first gaining institutional permission to attempt to produce stem cell lines via somatic cell nuclear transfer (SCNT), two Harvard researchers and a former Harvard postdoctoral fellow have closed the loop with a flurry of new studies and a commentary in several leading journals.
Rebecca M. Henderson of the Harvard Business School and Douglas Melton of the Faculty of Arts and Sciences and the Harvard Medical School were named University Professors in recognition of their dedication to teaching and scholarship that crosses academic boundaries.
Harvard stem cell researchers have succeeded in reprogramming adult mouse skin cells directly into the type of motor neurons damaged in amyotrophic lateral sclerosis, best known as Lou Gehrig's disease, and spinal muscular atrophy.
He’s an economist, a researcher, and a physician, and he’s about to become provost. On the day (April 15) that President Drew Faust announced that he would be Harvard’s next provost, Alan M. Garber ’76 sat down with the Gazette to talk about his career, his new role, and facilitating connections across traditional academic boundaries as the University evolves for the 21st century.
Stem cells being transfused into post-heart attack patients may not be developing into new heart muscle, but they still appear to be beneficial. Some stem cells in the bone marrow, called c-kit+ cells, appear capable of stimulating adult stem cells already present in the heart to repair damaged tissue.
Harvard stem cell researchers at Children’s Hospital Boston have taken two important steps toward development of a new way of treating melanoma, the most virulent form of skin cancer.
A group of Harvard Stem Cell Institute researchers in the Department of Stem Cell and Regenerative Biology has discovered that excitatory neurons control the positioning of inhibitory neurons in the brain in a process critically important for generating balanced circuitry and proper cortical response.
A team of Harvard Stem Cell Institute (HSCI) researchers, in collaboration with scientists at Columbia University, have demonstrated that many iPS cells (stem cells created by reprogramming adult cells) are the equal of human embryonic stem cells in creating human motor neurons, the cells destroyed in a number of neurological diseases, including Parkinson’s.
It has long been a given that adult humans — and mammals in general — lack the capacity to grow new nephrons, the kidney’s delicate blood filtering tubules, which has meant that dialysis, and ultimately kidney transplantation, is the only option for the more than 450,000 Americans who have kidney failure.
Provost Steven E. Hyman, who spurred an expansion of interdisciplinary research at Harvard and has overseen the revitalization of the University’s libraries and many of its museums and cultural institutions, plans to leave his post after nearly a decade.
An interdisciplinary group of leading Harvard geneticists and stem cell researchers has found a new genetic aspect of cell reprogramming that may ultimately help in the fine-tuning of induced pluripotent stem cells (iPS) into specific cell types.
A group of Harvard Stem Cell Institute researchers has made such a significant leap forward in reprogramming human adult cells that HSCI co-director Douglas Melton said the institute will immediately begin using the new method to make patient- and disease-specific induced pluripotent stem cells, known as iPS cells.
Faculty members at Harvard and its affiliated hospitals have been awarded the National Institutes of Health New Innovators awards for promising research by young researchers, and Transformative grants, for groundbreaking work by established researchers.